JP2016510804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510804A5 JP2016510804A5 JP2015562338A JP2015562338A JP2016510804A5 JP 2016510804 A5 JP2016510804 A5 JP 2016510804A5 JP 2015562338 A JP2015562338 A JP 2015562338A JP 2015562338 A JP2015562338 A JP 2015562338A JP 2016510804 A5 JP2016510804 A5 JP 2016510804A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- receptor antagonist
- pde3
- acute
- muscarinic receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 9
- 239000003149 muscarinic antagonist Substances 0.000 claims 9
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 claims 8
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 8
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 8
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 5
- 206010006440 Bronchial obstruction Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 208000038016 acute inflammation Diseases 0.000 claims 4
- 230000006022 acute inflammation Effects 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 208000037976 chronic inflammation Diseases 0.000 claims 4
- 230000006020 chronic inflammation Effects 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- -1 2,4,6-trimethylphenylimino Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 claims 1
- HWGNYZINNUCSQA-UHFFFAOYSA-N 2,3-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=CC=C2C3=CCNC(=O)N3C=CC2=C1 HWGNYZINNUCSQA-UHFFFAOYSA-N 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- OCAQSCOTLKDCIJ-UHFFFAOYSA-N C1CNC(N2C1=C1C=CC=CC1CC2)=O Chemical compound C1CNC(N2C1=C1C=CC=CC1CC2)=O OCAQSCOTLKDCIJ-UHFFFAOYSA-N 0.000 claims 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- FVTWTVQXNAJTQP-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol Chemical compound C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940015042 glycopyrrolate Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- 229960001361 ipratropium bromide Drugs 0.000 claims 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims 1
- 229960000797 oxitropium Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims 1
- 229960004633 pirenzepine Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960002646 scopolamine Drugs 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229950004351 telenzepine Drugs 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- 229960000257 tiotropium bromide Drugs 0.000 claims 1
- 229960004258 umeclidinium Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799177P | 2013-03-15 | 2013-03-15 | |
| US61/799,177 | 2013-03-15 | ||
| PCT/GB2014/050834 WO2014140648A1 (en) | 2013-03-15 | 2014-03-17 | Drug combination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510804A JP2016510804A (ja) | 2016-04-11 |
| JP2016510804A5 true JP2016510804A5 (https=) | 2017-04-27 |
| JP6560986B2 JP6560986B2 (ja) | 2019-08-14 |
Family
ID=50382477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562338A Active JP6560986B2 (ja) | 2013-03-15 | 2014-03-17 | 複合製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9700558B2 (https=) |
| EP (2) | EP2968313B1 (https=) |
| JP (1) | JP6560986B2 (https=) |
| KR (1) | KR102177982B1 (https=) |
| CN (1) | CN105142638B (https=) |
| AU (1) | AU2014229739B2 (https=) |
| CA (2) | CA2902403C (https=) |
| CY (2) | CY1120020T1 (https=) |
| DK (2) | DK2968312T3 (https=) |
| ES (2) | ES2660317T3 (https=) |
| HR (1) | HRP20180684T1 (https=) |
| HU (2) | HUE038899T2 (https=) |
| IL (1) | IL240846A0 (https=) |
| LT (1) | LT2968313T (https=) |
| MX (1) | MX374412B (https=) |
| NO (2) | NO2997033T3 (https=) |
| PL (2) | PL2968313T3 (https=) |
| PT (2) | PT2968312T (https=) |
| RS (1) | RS57075B1 (https=) |
| RU (1) | RU2666624C2 (https=) |
| SI (2) | SI2968312T1 (https=) |
| SM (1) | SMT201800134T1 (https=) |
| TR (1) | TR201802725T4 (https=) |
| WO (2) | WO2014140648A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968313B1 (en) | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| DK3142701T3 (en) | 2014-05-12 | 2018-08-13 | Verona Pharma Plc | New treatment |
| US20170119744A1 (en) * | 2014-06-18 | 2017-05-04 | Cipla Limited | Pharmaceutical Composition Comprising a Beta-2-Agonist and Anticholinergic Agent |
| CN110051627A (zh) | 2014-09-15 | 2019-07-26 | 维罗纳制药公司 | 包含rpl554的液体吸入制剂 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| US9827288B2 (en) * | 2015-09-21 | 2017-11-28 | Mycomagic Biotechnology Co., Ltd. | Method for treating a refractory or relapsed lung cancer |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| WO2020077333A1 (en) | 2018-10-12 | 2020-04-16 | Ppg Industries Ohio, Inc. | Compositions containing thermally conductive fillers |
| WO2020150460A1 (en) * | 2019-01-18 | 2020-07-23 | Milne Iii Donald A | Micronized aspirin formulation |
| GB201911517D0 (en) | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| AU2021208129A1 (en) * | 2020-01-15 | 2022-08-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition of tricyclic PDE3/PDE4 dual inhibitor compound |
| GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
| CN113975237B (zh) * | 2020-07-27 | 2024-12-20 | 盈科瑞（天津）创新医药研究有限公司 | 阿地溴铵吸入型冻干剂及其制备方法 |
| CN116917287A (zh) | 2021-04-29 | 2023-10-20 | 苏州盛迪亚生物医药有限公司 | 异喹啉酮类化合物及其用途 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024033625A1 (en) * | 2022-08-08 | 2024-02-15 | Verona Pharma Plc | Ensifentrine (rpl-554) for increasing trough lung function |
| CN120787157A (zh) * | 2022-10-20 | 2025-10-14 | 维罗纳制药公司 | 使用恩塞芬汀治疗特发性肺纤维化 |
| CN120897742A (zh) * | 2022-11-15 | 2025-11-04 | 福睿德姆生物科学公司 | 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
| US20250073240A1 (en) * | 2023-09-06 | 2025-03-06 | Verona Pharma Plc | New treatment |
| WO2025093848A1 (en) * | 2023-11-01 | 2025-05-08 | Verona Pharma Plc | Ensifentrine for treating bronchiectasis |
| CN117457114B (zh) * | 2023-12-25 | 2024-03-12 | 大连锦辉盛世科技有限公司 | 一种西药药学成分数据智能存储管理方法 |
| US20250249007A1 (en) * | 2024-02-07 | 2025-08-07 | Verona Pharma Plc | Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| WO1992022286A1 (en) | 1991-06-12 | 1992-12-23 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| EP0617610B1 (en) | 1991-12-18 | 1997-03-19 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| DE19626373A1 (de) * | 1996-07-02 | 1998-01-08 | Boehringer Ingelheim Kg | Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| ID27887A (id) | 1998-04-18 | 2001-05-03 | Glaxo Group Ltd | Formulasi aerosol farmasi |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| ES2208310T3 (es) | 1999-03-31 | 2004-06-16 | Vernalis Limited | Derivados de pirimido(6,1-a) isoquinolin-4-ona. |
| PT1169019E (pt) | 1999-04-14 | 2003-07-31 | Glaxo Group Ltd | Formulacao farmaceutica em aerossol |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| EP1366025B1 (en) | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
| JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| WO2005074982A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| ATE474601T1 (de) * | 2004-05-31 | 2010-08-15 | Almirall Sa | Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| CN1843453A (zh) * | 2005-04-06 | 2006-10-11 | 上海绿谷（集团）有限公司 | 一种治疗不孕症的中药组合物及其制备方法 |
| WO2007045980A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type iv inhibitors |
| EP2111861A1 (en) * | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
| WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| GB0919742D0 (en) * | 2009-11-11 | 2009-12-30 | Millipore Corp | Optical sensor |
| PH12013500261A1 (en) * | 2010-08-09 | 2013-03-04 | Verona Pharma Plc | Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| EP2968313B1 (en) | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
-
2014
- 2014-03-17 EP EP14712717.9A patent/EP2968313B1/en active Active
- 2014-03-17 DK DK14712716.1T patent/DK2968312T3/en active
- 2014-03-17 RS RS20180229A patent/RS57075B1/sr unknown
- 2014-03-17 ES ES14712717.9T patent/ES2660317T3/es active Active
- 2014-03-17 CA CA2902403A patent/CA2902403C/en active Active
- 2014-03-17 MX MX2015011778A patent/MX374412B/es active IP Right Grant
- 2014-03-17 JP JP2015562338A patent/JP6560986B2/ja active Active
- 2014-03-17 HU HUE14712716A patent/HUE038899T2/hu unknown
- 2014-03-17 SI SI201430689T patent/SI2968312T1/en unknown
- 2014-03-17 SM SM20180134T patent/SMT201800134T1/it unknown
- 2014-03-17 RU RU2015144083A patent/RU2666624C2/ru active
- 2014-03-17 TR TR2018/02725T patent/TR201802725T4/tr unknown
- 2014-03-17 WO PCT/GB2014/050834 patent/WO2014140648A1/en not_active Ceased
- 2014-03-17 DK DK14712717.9T patent/DK2968313T3/en active
- 2014-03-17 KR KR1020157028970A patent/KR102177982B1/ko active Active
- 2014-03-17 PL PL14712717T patent/PL2968313T3/pl unknown
- 2014-03-17 CN CN201480015150.8A patent/CN105142638B/zh active Active
- 2014-03-17 LT LTEP14712717.9T patent/LT2968313T/lt unknown
- 2014-03-17 CA CA2902400A patent/CA2902400C/en active Active
- 2014-03-17 PL PL14712716T patent/PL2968312T3/pl unknown
- 2014-03-17 EP EP14712716.1A patent/EP2968312B1/en active Active
- 2014-03-17 US US14/771,109 patent/US9700558B2/en active Active
- 2014-03-17 US US14/771,097 patent/US9717732B2/en active Active
- 2014-03-17 ES ES14712716.1T patent/ES2666098T3/es active Active
- 2014-03-17 PT PT147127161T patent/PT2968312T/pt unknown
- 2014-03-17 WO PCT/GB2014/050833 patent/WO2014140647A1/en not_active Ceased
- 2014-03-17 PT PT147127179T patent/PT2968313T/pt unknown
- 2014-03-17 AU AU2014229739A patent/AU2014229739B2/en active Active
- 2014-03-17 HU HUE14712717A patent/HUE037275T2/hu unknown
- 2014-03-17 HR HRP20180684TT patent/HRP20180684T1/hr unknown
- 2014-03-17 SI SI201430643T patent/SI2968313T1/en unknown
- 2014-04-18 NO NO14798188A patent/NO2997033T3/no unknown
- 2014-11-12 NO NO14798816A patent/NO3068699T3/no unknown
-
2015
- 2015-08-26 IL IL240846A patent/IL240846A0/en unknown
-
2017
- 2017-06-05 US US15/614,440 patent/US10471063B2/en active Active
-
2018
- 2018-03-12 CY CY20181100299T patent/CY1120020T1/el unknown
- 2018-04-26 CY CY20181100438T patent/CY1120346T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510804A5 (https=) | ||
| RU2015144083A (ru) | Комбинация лекарственных средств | |
| JP2018505192A5 (https=) | ||
| AU2022201816A8 (en) | Pyrrolopyrimidines as CFTR potentiators | |
| JP2012503668A5 (https=) | ||
| JP2017528479A5 (https=) | ||
| JP2011144201A5 (https=) | ||
| JP2012515720A5 (https=) | ||
| JP2016534153A5 (https=) | ||
| JP2010518122A5 (https=) | ||
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| JP2013542940A5 (https=) | ||
| JP2015519356A5 (https=) | ||
| EP2682108A3 (en) | Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component | |
| JP2014507474A5 (https=) | ||
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| JP2013500977A5 (https=) | ||
| EP2682097A3 (en) | Dry Powder Inhalers Comprising A Carrier Other Than Lactose | |
| JP2015514739A5 (https=) | ||
| WO2011093819A3 (en) | New pharmaceutical combination comprising tiotropium | |
| PE20170073A1 (es) | Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd | |
| WO2011093820A3 (en) | A pharmaceutical combination comprising tiotropium | |
| PE20142441A1 (es) | Nueva dosificacion y formulacion | |
| JP2014520874A5 (https=) | ||
| Bilton et al. | Inhaled Liposomal Ciprofloxacin Hydrochloride Significantly Reduces Sputum Pseudomonas Aeruginosa Density in CF and Non-CF Bronchiectasis. |